基本信息
浏览量:326
职业迁徙
个人简介
Dr. Vonderheide is a distinguished scientist and clinician who has deciphered mechanisms of cancer immune surveillance and developed novel cancer therapeutics, particularly in pancreatic cancer. He is well-recognized for driving the development of agonist CD40 antibodies, now in later stage clinical trials as potential immune therapy of cancer. Dr. Vonderheide discovered telomerase as a universal tumor antigen and has led the efforts to develop telomerase vaccination for both therapy and the prevention of cancer in healthy individuals. He has helped lead a team to show that stereotactic radiation therapy in combination with dual checkpoint blockade represents a synergistic path for immune activation in cancer. Dr. Vonderheide merges his clinical investigations with rigorous studies in mouse models or other laboratory systems. Dr. Vonderheide has been continuously funded by the NCI, and his high-impact findings have been published in Nature, Science, Cell and the New England Journal of Medicine.
RESEARCH INTERESTS
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
RESEARCH DETAILS
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
RESEARCH INTERESTS
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.
RESEARCH DETAILS
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.
研究兴趣
论文共 407 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): S92-S92
引用0浏览0引用
0
0
Margaret E. Haerr,Samuel I. Kim, Charu Arora, Kyle P. Gribbin,Robert H. Vonderheide,Katelyn T. Byrne
Cancer Researchno. 6_Supplement (2024): 6597-6597
Cancer discoveryno. 4 (2024): 600-604
Il-Kyu Kim,Mark S. Diamond,Salina Yuan,Samantha B. Kemp,Benjamin M. Kahn,Qinglan Li, Jeffrey H. Lin,Jinyang Li,Robert J. Norgard,Stacy K. Thomas, Maria Merolle,Takeshi Katsuda,
Nature Communicationsno. 1 (2024): 1-16
Carmen Guerra,Peter Edward Gabriel,Abigail Doucette, Colleen M. Grosso, Armenta L. Washington,Emily Verderame,Claudia Melendez, Christina Wooden,Daniel Lee,Linda White Nunes,Christine E. Edmonds,Brian S. Englander,
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): e18669-e18669
引用0浏览0引用
0
0
Albert Lo,Liang-Chuan S. Wang,John Scholler,James Monslow,Diana Avery,Kheng Newick, Shaun O'Brien, Rebecca A. Evans,David J. Bajor,Cynthia Clendenin,Amy C. Durham,Elizabeth L. Buza,
crossref(2023)
Albert Lo,Liang-Chuan S. Wang,John Scholler,James Monslow,Diana Avery,Kheng Newick, Shaun O'Brien, Rebecca A. Evans,David J. Bajor,Cynthia Clendenin, Amy C. Durham, Elizabeth L. Buza,
crossref(2023)
Rafael Winograd,Katelyn T. Byrne,Rebecca A. Evans,Pamela M. Odorizzi, Anders R.L. Meyer,David L. Bajor,Cynthia Clendenin,Ben Z. Stanger, Emma E. Furth,E. John Wherry,Robert H. Vonderheide
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn